Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 160.

Journal Article

Al-Sawaf, Othman, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Herling, Carmen D., Hoechstetter, Manuela, Fink, Anna-Maria, von Tresckow, Julia, Langerbeins, Petra, Cramer, Paula, Stilgenbauer, Stephan, Wendtner, Clemens M., Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2018). Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br. J. Haematol., 183 (5). S. 727 - 736. HOBOKEN: WILEY. ISSN 1365-2141

Al-Sawaf, Othman, Bazeos, Alexandra, Robrecht, Sandra, Bahlo, Jasmin, Gower, Craig, Fink, Anna-Maria, Tresckow, Julia, Cramer, Paula, Langerbeins, Petra, Kutsch, Nadine, Humphrey, Kathryn, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2019). Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). Am. J. Hematol., 94 (9). S. 1002 - 1007. HOBOKEN: WILEY. ISSN 1096-8652

Al-Sawaf, Othman, Eichhorst, Barbara and Hallek, Michael (2020). Chronic lymphocytic leukemia. Onkologe, 26 (5). S. 465 - 477. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Al-Sawaf, Othman, Eichhorst, Barbara and Hallek, Michael (2020). Chronic lymphocytic leukemia. Internist, 61 (3). S. 277 - 288. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Al-Sawaf, Othman, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2016). Targeted Therapy of CLL. Oncol. Res. Treat., 39 (12). S. 768 - 777. BASEL: KARGER. ISSN 2296-5262

Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Gentile, Brittany ORCID: 0000-0002-6302-5593, Devine, Jacob, Zhang, Can, Sail, Kavita, Tandon, Maneesh, Fink, Anna-Maria, Kutsch, Nadine, Wendtner, Clemens-Martin, Eichhorst, Barbara, Hallek, Michael and Fischer, Kirsten (2021). Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. Am. J. Hematol., 96 (9). S. 1112 - 1120. HOBOKEN: WILEY. ISSN 1096-8652

Al-Sawaf, Othman, Lilienweiss, Esther, Bahlo, Jasmin, Robrecht, Sandra, Fink, Anna-Maria, Patz, Michaela, Tandon, Maneesh, Jiang, Yanwen, Schary, William, Ritgen, Matthias, Tausch, Eugen, Stilgenbauer, Stephan, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael and Kreuzer, Karl-Anton (2020). High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood, 135 (11). S. 866 - 871. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Robrecht, Sandra, Bahlo, Jasmin, Fink, Anna-Maria, Cramer, Paula, Maurer, Christian, Bergmann, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Jaeger, Ulrich, Wendtner, Clemens, Fischer, Kirsten, Goede, Valentin, Hallek, Michael, Eichhorst, Barbara, Hopfinger, Georg, Doehner, Hartmut and Kiehl, Michael (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis of the German CLL Study Group (GCLLSG). Leuk. Lymphoma, 58. S. 62 - 64. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Al-Sawaf, Othman, Robrecht, Sandra, Bahlo, Jasmin, Fink, Anna-Maria, Cramer, Paula, von Tresckow, Julia, Lange, Elisabeth, Kiehl, Michael, Dreyling, Martin, Rittgen, Matthias, Duerig, Jan, Fischer, Kirsten, Stilgenbauer, Stephan, Wendtner, Clemens, Goede, Valentin, Hallek, Michael and Eichhorst, Barbara (2020). Richter transformation in CLL: a meta-analysis of GCLLSG trials. Leuk. Lymphoma, 61. S. 98 - 101. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers ORCID: 0000-0002-5577-3516, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael and Fischer, Kirsten (2021). Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J. Clin. Oncol., 39 (36). S. 4049 - 4062. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna Maria, Robrecht, Sandra, Tausch, Eugen, Schary, William L., Ritgen, Matthias, Wendtner, Clemens Martin, Kreuzer, Karl A., Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael J. and Fischer, Kirsten (2020). Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna-Maria, Robrecht, Sandra, Samoylova, Olga, Liberati, Anna M., Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Du, Katell, Fogliatto, Laura M., Niemann, Carsten U., Weinkove, Robert, Robinson, Sue, Kipps, Thomas J., Tausch, Eugen, Schary, William, Ritgen, Matthias, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael and Fischer, Kirsten (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol., 21 (9). S. 1188 - 1201. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Armand, Philippe, Murawski, Niels, Molin, Daniel, Zain, Jasmine, Eichhorst, Barbara, Gulbas, Zafer, Hawkes, Eliza A., Pagel, John M., Phillips, Tycel ORCID: 0000-0003-2143-9672, Ribrag, Vincent, Svoboda, Jakub, Stathis, Anastasios, Chatterjee, Arkendu, Orlowski, Robert, Marinello, Patricia and Christian, Beth (2020). Pembrolizumab in relapsed or refractory Richter syndrome. Br. J. Haematol., 190 (2). S. E117 - 4. HOBOKEN: WILEY. ISSN 1365-2141

Bahlo, Jasmin, Pflug, Natali, Elter, Thomas, Bauer, Kathrin, Eichhorst, Barbara, Bergmann, Manuela, Busch, Raymonde, Doehner, Hartmut, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten and Hallek, Michael (2011). Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials. Blood, 118 (21). S. 1219 - 1221. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Beckmann, Laura ORCID: 0000-0001-5207-8991, Berg, Valeska, Dickhut, Clarissa, Sun, Clare ORCID: 0000-0001-8498-4729, Merkel, Olaf, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Robrecht, Sandra, Seifert, Marc, Guerreiro, Alexandra da Palma, Claasen, Julia, Loroch, Stefan, Oliverio, Matteo, Underbayev, Chingiz, Vaughn, Lauren, Thomalla, Daniel, Huelsemann, Malte F., Tausch, Eugen, Fischer, Kirsten, Fink, Anna Maria ORCID: 0000-0002-7669-7890, Eichhorst, Barbara, Sickmann, Albert ORCID: 0000-0002-2388-5265, Wendtner, Clemens M., Stilgenbauer, Stephan, Hallek, Michael, Wiestner, Adrian, Zahedi, Rene P. and Frenzel, Lukas P. (2021). MARCKS affects cell motility and response to BTK inhibitors in CLL. Blood, 138 (7). S. 544 - 557. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Braun, Andrejs ORCID: 0000-0003-0925-5598, Taylor-Weiner, Amaro, Jebaraj, Billy Michael Chelliah, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz, Scheffold, Annika, Johnston, Harvey E., Yeh, Ru-Fang, Klymenko, Tetyana, Tausch, Eugen, Eichhorst, Barbara, Bullinger, Lars ORCID: 0000-0002-5890-5510, Fischer, Kirsten, Weisser, Martin, Robak, Tadeusz ORCID: 0000-0002-3411-6357, Schneider, Christof, Gribben, John, Dahal, Lekh N., Carter, Mathew J., Elemento, Olivier, Landau, Dan A., Neuberg, Donna S., Cragg, Mark S., Benner, Axel, Hallek, Michael, Wu, Catherine J., Doehner, Hartmut, Stilgenbauer, Stephan and Mertens, Daniel (2021). Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nat. Commun., 12 (1). BERLIN: NATURE PORTFOLIO. ISSN 2041-1723

Boeitcher, Sebastian, Ritgen, Matthias, Fischer, Kirsten, Stilgenbauer, Stephan, Busch, Raymonde, Fingerle-Rowson, Gunter R., Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Wenger, Michael K., Mendila, Myriam, Wendtner, Clemens, Eichhorst, Barbara, Doehner, Hartmut, Hallek, Michael and Kneba, Michael (2011). Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups-Results From the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 775 - 776. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Brown, Jennifer R., Eichhorst, Barbara, Ghia, Paolo, Kater, A. P., Li, Jianyong, Khurana, Sudha, Elhamy, Mostafa, Wang, Min Hui and Seymour, John F. (2020). Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL). Clin. Lymphoma Myeloma Leuk., 20. S. S221 - 2. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Lamanna, Nicole, O'Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Kazmierczak, Maciej, Jurczak, Wojciech, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda L., Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan (Der Yu), Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen and Shadman, Mazyar (2022). Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. Blood, 140. S. 19 - 24. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Brown, Jennifer. R. R., Eichhorst, Barbara, Hillmen, Peter, Jurczak, Wojciech, Kazmierczak, Maciej, Lamanna, Nicole, O'Brien, Susan. M. M., Tam, Constantine. S. S., Qiu, Lugui, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda, Ferrajoli, Alessandra, Ganly, Peter. S. S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte. A. A., Salmi, Tommi, Wang, Megan-Der-Yu, Fu, Lina., Li, Jessica, Wu, Kenneth, Cohen, Aileen and Shadman, Mazyar . Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med.. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfo, Lydia, Karakatsoulis, Georgios, Allsup, David ORCID: 0000-0001-6159-6109, Alonso Cabrero, Alejandro, Andres, Martin ORCID: 0000-0001-9891-2988, Antic, Darko, Baile, Monica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuellar-Garcia, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca ORCID: 0000-0002-4294-8145, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik ORCID: 0000-0001-8905-0220, Furstenau, Moritz, Garcia-Marco, Jose A., Garcia-Serra, Rocio, Gentile, Massimo, Gimeno, Eva, Glenthoj, Andreas, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Angel Hernandez-Rivas, Jose, Herold, Tobias ORCID: 0000-0002-9615-9432, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicinska, Elzbieta ORCID: 0000-0002-4797-8001, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh ORCID: 0000-0003-3754-7774, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Miras, Fatima, Morawska, Marta ORCID: 0000-0001-6836-2903, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Arturo Pavlovsky, Miguel, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Simkovic, Martin ORCID: 0000-0003-0331-5334, Spacek, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea ORCID: 0000-0003-0271-7200, Vitale, Candida, Wasik-Szczepanek, Ewa, Wrobel, Tomasz ORCID: 0000-0002-6612-3535, Yanez San Segundo, Lucrecia, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foa, Robin, Cuneo, Antonio, Stamatopoulos, Kostas and Ghia, Paolo (2021). COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 35 (12). S. 3444 - 3455. LONDON: SPRINGERNATURE. ISSN 1476-5551

Chyla, Brenda, Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Puvvada, Soham, Wendtner, Clemens, Davids, Matthew S., Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Wierda, William and Hallek, Michael (2017). Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial. Leuk. Lymphoma, 58. S. 234 - 236. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, Bahlo, Jasmin, Eichhorst, Barbara, Fischer, Kirsten and Hallek, Michael (2014). Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual. Leuk. Res., 38 (3). S. 284 - 286. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835

Cramer, Paula, Eichhorst, Barbara, Reinhardt, Hans Christian and Hallek, Michael (2016). Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Pract. Res. Clin. Haematol., 29 (1). S. 111 - 122. OXFORD: ELSEVIER SCI LTD. ISSN 1532-1924

Cramer, Paula, Fink, Anna-Maria, Busch, Raymonde, Eichhorst, Barbara, Wendtner, Clemens-Martin, Pflug, Natali, Schubert, Friederike, Doehner, Hartmut, Rieger, Michael, Kneba, Michael, Mayer, Jiri, Hallek, Michael and Fischer, Kirsten (2011). Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 1235 - 1236. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Cramer, Paula ORCID: 0000-0003-4046-9922, Furstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Bottcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Bruggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2022). Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG) a multicentre, open-label, phase 2 trial. Lancet Haematol., 9 (10). S. E745 - 11. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Cramer, Paula, Hallek, Michael and Eichhorst, Barbara (2016). State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia. Oncol. Res. Treat., 39 (1-2). S. 25 - 32. BASEL: KARGER. ISSN 2296-5262

Cramer, Paula, Isfort, Susanne, Bahlo, Jasmin, Stilgenbauer, Stephan, Doehner, Hartmut, Bergmann, Manuela, Stauch, Martina, Kneba, Michael, Lange, Elisabeth, Langerbeins, Petra, Pflug, Natali, Kovacs, Gabor, Goede, Valentin, Fink, Anna-Maria, Elter, Thomas, Fischer, Kirsten, Wendtner, Clemens-Martin, Hallek, Michael and Eichhorst, Barbara (2015). Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica, 100 (11). S. 1451 - 1460. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Cramer, Paula, Langerbeins, Petra, Eichhorst, Barbara and Hallek, Michael (2016). Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). Eur. J. Haematol., 96 (1). S. 9 - 19. HOBOKEN: WILEY. ISSN 1600-0609

Cramer, Paula, Langerbeins, Petra, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2016). Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all? Leuk. Lymphoma, 57 (5). S. 987 - 991. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, Tausch, Eugen, von Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Furstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Pelzer, Benedikt W., Fink, Anna Maria ORCID: 0000-0002-7669-7890, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2021). Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood, 138 (19). S. 1805 - 1817. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2018). CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol., 14 (6). S. 499 - 514. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Engelke, Anja, Langerbeins, Petra, Wesselmann, Johanna Sofie, Annolleck, Tanja, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2015). CLL2-BIG, -BAG, -BCG and -BIO: a series of four phase-II trials evaluating a sequential tailored and targeted regimen aiming for total eradication of MRD in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Leuk. Lymphoma, 56. S. 143 - 145. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Langerbeins, Petra, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Kreuzer, Karl-Anton, Rittgen, Matthias, Kneba, Michael, Wendtner, Clemens, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2017). Sequential treatment with bendamustine, followed by obinutuzumab (GA101) and venetoclax (ABT-199) in patients with chronic lymphocytic leukemia (CLL): results of the CLL2-BAG phase-II-trial of the German CLL study group (GCLLSG). Leuk. Lymphoma, 58. S. 149 - 151. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Al-Sawaf, Othman, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Tausch, Eugen, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2018). Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol., 19 (9). S. 1215 - 1229. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Fuerstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2018). Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Eichhorst, Barbara and Hallek, Michael (2020). Current Diagnosis and Treatment of Chronic Lymphocytic Leukaemia. Dtsch. Med. Wochenschr., 145 (16). S. 1139 - 1145. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413

Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz ORCID: 0000-0002-6593-0140, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO). Haematologica, 106 (2). S. 543 - 555. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Davids, Matthew Steven, Seymour, John Francis, Roberts, Andrew Warwick, Eichhorst, Barbara, Kipps, Thomas J., Mato, Anthony R., Stilgenbauer, Stephan, Mobasher, Mehrdad, Desai, Monali Bhardwaj, Potluri, Jalaja, Pena, German E., Verdugo, Maria E., Nielsen, Jacqueline, Cyr, Aimee, Fleming, Leanne Lash and Hallek, Michael J. (2018). Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Dimier, Natalie, Delmar, Paul, Ward, Carol, Morariu-Zamfir, Rodica, Fingerle-Rowson, Guenter, Bahlo, Jasmin, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, van Dongen, Jacques J. M., Ritgen, Matthias, Boettcher, Sebastian, Langerak, Anton W., Kneba, Michael and Hallek, Michael (2018). A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood, 131 (9). S. 955 - 963. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara (2018). Chronic Lymphocytic Leukemia: Chemoimmunotherapy is over? No. Clin. Lymphoma Myeloma Leuk., 18. S. S120 - 3. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Eichhorst, Barbara (2022). Ibrutinib frontline in young patients with CLL. Blood, 140 (2). S. 80 - 82. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara (2021). Vaccination against COVID-19: a challenge in CLL. Blood, 137 (23). S. 3153 - 3155. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara, Bahlo, Jasmin, Fink, Anna Maria, Pfreundschuh, Michael, Hebart, Holger, Maschmeyer, Georg, Jentsch-Ulrich, Kathleen, Doerfel, Steffen, Westermann, Anne, Zey, Aline, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Kreuzer, Karl-Anton, Doehner, Hartmut, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2014). Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara, Cramer, Paula and Hallek, Michael (2016). Initial therapy of chronic lymphocytic leukemia. Semin. Oncol., 43 (2). S. 241 - 251. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. ISSN 1532-8708

Eichhorst, Barbara, Fink, Anna Maria, Busch, Raymonde, Kovacs, Gabor, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael G., Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg R. A., Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Trneny, Marek, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl Anton, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2014). Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara, Fink, Anna-Maria, Bahlo, Jasmin, Busch, Raymonde, Kovacs, Gabor, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael, Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg, Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Trneny, Marek ORCID: 0000-0002-6952-6073, Fischer, Kirsten, Doehner, Harmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2016). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol., 17 (7). S. 928 - 943. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Eichhorst, Barbara, Fuerstenau, Moritz and Hallek, Michael (2019). Relapsed disease and aspects of undetectable MRD and treatment discontinuation. Hematol.-Am. Soc. Hematol. Educ. Program. S. 482 - 490. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1520-4383

Eichhorst, Barbara and Ghia, Paolo (2021). EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia. Hemasphere, 5 (1). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Eichhorst, Barbara and Hallek, Michael (2016). Novel therapy concepts for chronic lymphocytic leukemia. Onkologe, 22 (4). S. 283 - 293. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Eichhorst, Barbara and Hallek, Michael (2016). Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematol.-Am. Soc. Hematol. Educ. Program. S. 149 - 156. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1520-4383

Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2018). Management of unfit elderly patients with chronic lymphocytic leukemia. Eur. J. Intern. Med., 58. S. 7 - 14. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1879-0828

Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2016). New treatment approaches in CLL: Challenges and opportunities in the elderly. J. Geriatr. Oncol., 7 (5). S. 375 - 383. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1879-4076

Einsele, Hermann, Steutel, Han, Eichhorst, Barbara, Gobeler, Maria-Elisabeth, Hochhaus, Andreas, Nickel, Lars, von Messling, Veronika, Deggerich, Anke and Nettekoven, Gerd (2022). Clinical Trials in Hematology and Oncology. Oncol. Res. Treat., 45. S. 6 - 33. BASEL: KARGER. ISSN 2296-5262

Fink, Anna, Busch, Raymonde, Pflug, Natali, Boettcher, Sebastian, Winkler, Dirk, Buehler, Andreas, Ritgen, Matthias, Fischer, Kirsten, Eichhorst, Barbara, Wendtner, Clemens-Martin, Mendila, Myriam, Wenger, Michael K., Doehner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2011). Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 446 - 448. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Fink, Anna Maria, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo ORCID: 0000-0003-3750-7342, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Dohner, Hartmut, Kneba, Michael, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2017). Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol., 4 (10). S. E475 - 12. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Fink, Anna Maria, Bahlo, Jasmin, Sandra, Robrecht, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ulrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens Martin, Noesslinger, Thomas, Ghia, Paolo, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Kreuzer, Karl-Anton, Dohner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2016). Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fink, Anna-Maria, Robrecht, Sandra, Bahlo, Jasmin, Fuerstenau, Moritz, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens Martin, Noesslinger, Thomas, Ghia, Paolo, Kater, Arnon, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Rittgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2020). Long-term efficacy and safety of maintenance with lenalidomide in patients with chronic lymphocytic leukaemia and a high risk of progression after first-line immunochemotherapy. Leuk. Lymphoma, 61. S. 272 - 274. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Fischer, Kirsten, Al-Sawaf, Othman, Fink, Anna-Maria, Dixon, Mark, Bahlo, Jasmin, Warburton, Simon, Kipps, Thomas J., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Dreyling, Martin H., Opat, Stephen, Owen, Carolyn J., Lopez, Javier, Humphrey, Kathryn, Humerickhouse, Rod A., Tausch, Eugen, Eichhorst, Barbara, Wendtner, Clemens-M., Langerak, Anton W., van Dongen, Jacques J. M., Ritgen, Matthias, Boettcher, Sebastian, Stilgenbauer, Stephan, Goede, Valentin, Mobasher, Mehrdad and Hallek, Michael (2016). Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten, Al-Sawaf, Othman, Fink, Anna-Maria, Dixon, Mark, Bahlo, Jasmin, Warburton, Simon, Kipps, Thomas J., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Seiler, Till, Opat, Stephen, Owen, Carolyn, Lopez, Javier, Humphrey, Kathryn, Humerickhouse, Rod, Tausch, Eugen, Frenzel, Lukas, Eichhorst, Barbara, Wendtner, Clemens-M., Stilgenbauer, Stephan, Langerak, Anton W., van Dongen, Jacque J. M., Boettcher, Sebastian, Ritgen, Matthias, Goede, Valentin, Mobasher, Mehrdad and Hallek, Michael (2017). Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 129 (19). S. 2702 - 2706. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna Maria, Goede, Valentin, Herling, Carmen Diana, Cramer, Paula, Langerbeins, Petra, von Tresckow, Julia, Engelke, Anja, Maurer, Christian, Kovacs, Gabor, Herling, Marco, Tausch, Eugen, Kreuzer, Karl-Anton, Eichhorst, Barbara, Boettcher, Sebastian, Seymour, John F., Ghia, Paolo ORCID: 0000-0003-3750-7342, Marlton, Paula, Kneba, Michael, Wendtner, Clemens-Martin, Doehner, Hartmut, Stilgenbauer, Stephan and Hallek, Michael (2016). Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood, 127 (2). S. 208 - 216. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten, Fink, Anna-Maria, Bishop, Helen, Dixon, Mark, Bahlo, Jasmin, Chol, Michael Y., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Dreyling, Martin, Seiler, Till, Opat, Stephen, Owen, Carolyn, Lopez, Javier, Sr., Kutsch, Nadine, Tausch, Eugen, Ritgen, Matthias, Humerickhouse, Rod A., Humphrey, Kathryn, Wenger, Michael K., Goede, Valentin, Eichhorst, Barbara, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Kipps, Thomas J. and Hallek, Michael (2015). Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase Ill Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, De Silva, Nisha, Eichhorst, Barbara and Hallek, Michael J. (2019). Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine? Hemasphere, 3 (5). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Fuerstenau, Moritz and Eichhorst, Barbara (2021). Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. Cancers, 13 (6). BASEL: MDPI. ISSN 2072-6694

Fuerstenau, Moritz, Fink, Anna Maria, Schilhabel, Anke, Weiss, Jonathan, Robrecht, Sandra, Eckert, Robert, de la Serna, Javier, Crespo, Marta ORCID: 0000-0002-7732-7808, Coscia, Marta, Vitale, Candida, Boettcher, Sebastian, Weppner, Gesche, Ritgen, Matthias, Stilgenbauer, Stephan, Tausch, Eugen, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara, Brueggemann, Monika and Herling, Carmen D. (2021). B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 137 (16). S. 2267 - 2272. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Fink, Anna-Maria, Herling, Carmen, Maurer, Christian, Kutsch, Nadine, De La Serna, Javier, Coscia, Marta, Crespo, Marta, Bosch, Francesc ORCID: 0000-0001-9241-2886, Noesslinger, Thomas, Ghia, Paolo, Kater, Arnon P., Ritgen, Matthias, Schilhabel, Anke, Stilgenbauer, Stephan, Tausch, Eugen, Fischer, Kirsten, Hallek, Michael J. and Eichhorst, Barbara (2018). B-cell acute lymphoblastic leukemia (BALL) in CLL patients treated with lenalidomide. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Fuerstenau, Moritz, Giza, Adam, Stumpf, Thomas, Robrecht, Sandra, Maurer, Christian, Linde, Hartmut, Jacobasch, Lutz, Doerfel, Steffen, Aldaoud, Ali, von Tresckow, Julia, Koenigsmann, Michael, Gaska, Tobias, Kaiser, Ulrich, Harich, Hanns-Detlev, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Fink, Anna-Maria (2021). Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. Am. J. Hematol., 96 (12). S. E457 - 4. HOBOKEN: WILEY. ISSN 1096-8652

Fuerstenau, Moritz, Hallek, Michael and Eichhorst, Barbara (2019). Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica, 104 (11). S. 2144 - 2155. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Fuerstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Von Tresckow, Julia, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Doehner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, von Bergwelt-Baildon, Michael, Eichhorst, Barbara, Hallek, Michael and Theurich, Sebastian ORCID: 0000-0001-5706-8258 (2020). Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia, 34 (4). S. 1177 - 1182. LONDON: SPRINGERNATURE. ISSN 1476-5551

Fuerstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Von Tresckow, Julia, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Doehner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara and Theurich, Sebastian (2018). Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Langerbeins, Petra, De Silva, Nisha, Fink, Anna Maria, Robrecht, Sandra, von Tresckow, Julia, Simon, Florian, Hohloch, Karin, Droogendijk, Jolanda, van der Klift, Marjolein, van der Spek, Ellen, Illmer, Thomas, Schoettker, Bjoern, Fischer, Kirsten, Wendtner, Clemens M., Tausch, Eugen, Stilgenbauer, Stephan, Niemann, Carsten U., Gregor, Michael, Kater, Arnon P., Hallek, Michael and Eichhorst, Barbara (2020). COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia, 34 (8). S. 2225 - 2230. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Fuerstenau, Moritz, Simon, Florian, Cornely, Oliver A., Hicketier, Tillman, Eichhorst, Barbara, Hallek, Michael and Mellinghoff, Sibylle C. (2020). Invasive Aspergillosis in Patients Treated With Ibrutinib. Hemasphere, 4 (2). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Furstenau, Moritz, Bahlo, Jasmin, Fink, Anna-Maria, Lange, Elisabeth, Dreger, Peter, Dreyling, Martin, Hess, Georg, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Boettcher, Sebastian, Hallek, Michael and Eichhorst, Barbara (2018). Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, Van der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjorn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C., Lindstroem, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brueggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton and Kater, Arnon P. (2022). High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Furstenau, Moritz ORCID: 0000-0002-6593-0140, Weiss, Jonathan, Giza, Adam, Franzen, Fabian, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Schneider, Christof, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Schilhabel, Anke, Brueggemann, Monika, Eichhorst, Barbara, Hallek, Michael and Cramer, Paula ORCID: 0000-0003-4046-9922 (2022). Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clin. Cancer Res., 28 (19). S. 4203 - 4212. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Goede, Valentin, Bahlo, Jasmin, Chataline, Viktoria, Eichhorst, Barbara, Duerig, Jan, Stilgenbauer, Stephan, Kolb, Gerald, Honecker, Friedemann, Wedding, Ulrich and Hallek, Michael (2016). Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leuk. Lymphoma, 57 (4). S. 789 - 797. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Goede, Valentin, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Fink, Anna-Maria, Stilgenbauer, Stephan, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Wendtner, Clemens (2017). Cumulative Illness Rating Scale (CIRS) provides prognostic information beyond the International Prognostic Index for chronic lymphocytic leukemia (CLL-IPI): analysis of 3 randomized trials of the German CLL Study Group. Leuk. Lymphoma, 58. S. 96 - 99. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Goede, Valentin, Cramer, Paula, Busch, Raymonde, Bergmann, Manuela, Stauch, Martina, Hopfinger, Georg, Stilgenbauer, Stephan, Doehner, Hartmut, Westermann, Anne, Wendtner, Clemens M., Eichhorst, Barbara and Hallek, Michael (2014). Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica, 99 (6). S. 1095 - 1101. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Goede, Valentin, Fischer, Kirsten, Busch, Raymonde, Engelke, Anja, Eichhorst, Barbara, Wendtner, Clemens M., Chagorova, Tatiana, de la Serna, Javier, Dilhuydy, Marie-Sarah, Illmer, Thomas, Opat, Stephen, Owen, Carolyn J., Samoylova, Olga, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Doehner, Hartmut, Langerak, Anton W., Ritgen, Matthias, Kneba, Michael, Asikanius, Elina, Humphrey, Kathryn, Wenger, Michael and Hallek, Michael (2014). Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 370 (12). S. 1101 - 1111. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillermo, Doehner, Hartmut, Hillmen, Peter, Keating, Michael, Montserrat, Emili, Chiorazzi, Nicholas, Stilgenbauer, Stephan, Rai, Kanti R., Byrd, John C., Eichhorst, Barbara, O'Brien, Susan, Robak, Tadeusz, Seymour, John F. and Kipps, Thomas J. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131 (25). S. 2745 - 2761. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Hallek, Michael, Shanafelt, Tait D. and Eichhorst, Barbara (2018). Chronic lymphocytic leukaemia. Lancet, 391 (10129). S. 1524 - 1538. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X

Herling, Carmen D., Abedpour, Nima, Weiss, Jonathan, Schmitt, Anna, Jachimowicz, Ron Daniel, Merkel, Olaf ORCID: 0000-0001-5089-344X, Cartolano, Maria, Oberbeck, Sebastian, Mayer, Petra, Berg, Valeska, Thomalla, Daniel, Kutsch, Nadine, Stiefelhagen, Marius, Cramer, Paula, Wendtner, Clemens-Martin ORCID: 0000-0003-2866-2260, Persigehl, Thorsten, Saleh, Andreas, Altmueller, Janine, Nuernberg, Peter, Pallasch, Christian, Achter, Viktor, Lang, Ulrich, Eichhorst, Barbara, Castiglione, Roberta ORCID: 0000-0002-9828-4405, Schaefer, Stephan C., Buettner, Reinhard, Kreuzer, Karl-Anton, Reinhardt, Hans Christian, Hallek, Michael, Frenzel, Lukas P. and Peifer, Martin ORCID: 0000-0002-5243-5503 (2018). Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat. Commun., 9. LONDON: NATURE PUBLISHING GROUP. ISSN 2041-1723

Herling, Carmen D., Cymbalista, Florence, Gross-Ophoff-Mueller, Carolin, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Busch, Raymonde, Porcher, Raphael ORCID: 0000-0002-5277-4679, Cazin, Bruno, Dreyfus, Brigitte, Ibach, Stefan, Lepretre, Stephane, Fischer, Kirsten, Kaiser, Florian, Eichhorst, Barbara, Wentner, Clemens-Martin, Hoechstetter, Manuela A., Doehner, Hartmut, Leblond, Veronique, Kneba, Michael, Letestu, Remi, Boettcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael and Levy, Vincent (2020). Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia, 34 (8). S. 2038 - 2051. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W., Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny and Mobasher, Mehrdad (2018). High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Hoechstetter, Manuela A., Busch, Raymonde, Eichhorst, Barbara, Buhler, Andreas, Winkler, Dirk, Bahlo, Jasmin, Robrecht, Sandra, Eckart, Michael J., Vehling-Kaiser, Ursula, Jacobs, Georg, Jaeger, Ulrich, Hurtz, Hans Juergen, Hopfinger, Georg, Hartmann, Frank, Fuss, Harald, Abenhardt, Wolfgang, Blau, Ilona, Freier, Werner, Mueller, Lothar, Goebeler, Maria, Wendtner, Clemens, Fischer, Kirsten, Herling, Carmen D., Starck, Michael, Bentz, Martin, Emmerich, Bertold, Doehner, Hartmut, Stilgenbauer, Stephan and Hallek, Michael (2020). Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. Leukemia, 34 (4). S. 1038 - 1052. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Huber, Henriette, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Zhang, Can, Tausch, Eugen, Schneider, Christof, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Fuerstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna L., Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael ORCID: 0000-0002-7425-4455, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 139 (9). S. 1318 - 1330. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Jaramillo, Sonia, Agathangelidis, Andreas, Schneider, Christof, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Bloehdorn, Johannes, Hoechstetter, Manuela, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, Hallek, Michael, Doehner, Hartmut, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas and Stilgenbauer, Stephan (2020). Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group. Haematologica, 105 (11). S. 2598 - 2608. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Jebaraj, Billy Michael Chelliah, Tausch, Eugen, Landau, Dan A., Bahlo, Jasmin, Robrecht, Sandra, Taylor-Weiner, Amaro N., Bloehdorn, Johannes, Scheffold, Annika, Mertens, Daniel ORCID: 0000-0003-0227-7188, Boettcher, Sebastian, Kneba, Michael, Jaeger, Ulrich, Zenz, Thorsten, Wenger, Michael K., Fingerle-Rowson, Guenter, Wendtner, Clemens, Fink, Anna-Maria, Wu, Catherine J., Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan (2019). Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia, 33 (9). S. 2183 - 2195. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Jenke, Petra, Eichhorst, Barbara, Busch, Raymonde, Anheier, Nadine, Duehrsen, Ulrich, Duerig, Jan, Dreyling, Martin H., Bergmann, Manuela, Goebeler, Maria Elisabeth, Hurts, Hans Juergen, Stauch, Martina Beate, Stilgenbauer, Stephan, Doehner, Hartmut, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin and Hallek, Michael (2011). Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group. Blood, 118 (21). S. 1233 - 1235. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Julia, Von Tresckow, Carsten, Niemann, Kater, Arnon P., Bahlo, Jasmin, Farstenau, Moritz, Fink, Anna-Maria, Gregor, Michael, Thornton, Patrick, Tadmor, Tamar, Fischer, Kirsten, Ritgen, Matthias, Kreuzer, Karl A., Eldering, Eric, Stilgenbauer, Stephan, Van Oers, Marinus, Geisler, Christian, Hallek, Michael J. and Eichhorst, Barbara (2018). The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL). J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Julia, Von Tresckow, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Langerbeins, Petra, Fuerstenau, Moritz, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl A., Ritgen, Matthias, Boettcher, Sebastian, Wendtner, Clemens Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael J. (2018). Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kater, Arnon P., Eichhorst, Barbara, Owen, Carolyn, Jaeger, Ulrich, Chyla, Brenda, Lefebure, Marcus, Millen, Rosemary, Jiang, Yanwen, Thadani-Mulero, Maria and Seymour, John F. (2022). Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 140. S. 7010 - 7013. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kater, Arnon P., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Kipps, Thomas J., Owen, Carolyn, Boyer, Michelle, Humphrey, Kathryn, Punnoose, Elizabeth A., Wang, Jue, Chyla, Brenda, Verdugo, Maria E., Wu, Jenny, Jiang, Yanwen, Mobasher, Mehrdad and Seymour, John F. (2018). First Prospective Data on Impact of Minimal Residual Disease on Long - Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kater, Arnon P., Seymour, John F., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Owen, Carolyn, Verdugo, Maria, Wu, Jenny, Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad and Kipps, Thomas J. (2019). Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J. Clin. Oncol., 37 (4). S. 269 - 287. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter ORCID: 0000-0001-5617-4403, D'Rozario, James, Assouline, Sarit ORCID: 0000-0002-7638-1589, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn and Seymour, John F. (2020). Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J. Clin. Oncol., 38 (34). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kovacs, Gabor, Bahlo, Jasmin, Kluth, Sandra, Cramer, Paula, Fink, Anna-Maria, Fischer, Kirsten, Gross-Ophoff-Mueller, Carolin, Langerbeins, Petra, Maurer, Christian, von Tresckow, Julia, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Hallek, Michael, Eichhorst, Barbara and Goede, Valentin (2015). Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kovacs, Gabor, Boettcher, Sebastian, Bahlo, Jasmin, Kluth, Sandra, Ritgen, Matthias, Fink, Anna Maria, Stodden, Irene, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Doehner, Hartmut, Stilgenbauer, Stephan, Kneba, Michael, Fischer, Kirsten, Hallek, Michael and Eichhorst, Barbara (2014). Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kovacs, Gabor, Robrecht, Sandra, Fink, Anna Maria, Bahlo, Jasmin, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Langerbeins, Petra, Fingerle-Rowson, Gunter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Klapper, Wolfram, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara and Boettcher, Sebastian (2016). Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J. Clin. Oncol., 34 (31). S. 3758 - 3775. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kreuzer, Karl-Anton, Furman, Richard, Stilgenbauer, Stephan, Dubowy, Ronald, Kim, Yeonhee, Munugalavadla, Veerendra, Lilienweisz, Esther, Reinhardt, Hans Christian, Cramer, Paula, Eichhorst, Barbara, Hillmen, Peter, O'Brien, Susan, Pettitt, Andrew and Hallek, Michael (2017). Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab. Leuk. Lymphoma, 58. S. 167 - 169. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kreuzer, Karl-Anton, Furman, Richard R., Stilgenbauer, Stephan, Dubowy, Ronald L., Kim, Yeonhee, Munugalavadla, Veerendra, Lilienweiss, Esther, Reinhardt, Hans Christian, Cramer, Paula, Eichhorst, Barbara, Hillmen, Peter, O'Brien, Susan M., Pettitt, Andrew R. and Hallek, Michael (2020). The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia, 34 (1). S. 296 - 301. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Kron, Florian, Kutsch, Nadine, Kostenko, Anna, Dohle, Ines, Glossmann, Jan-Peter, Mueller, Dirk, Heimann, Sebastian M., Bahlo, Jasmin, von Bergwelt-Baildon, Michael, Eichhorst, Barbara, Wolf, Juergen, Hallek, Michael and Zander, Thomas (2017). Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective. Eur. J. Haematol., 98 (2). S. 169 - 177. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0609

Kutsch, Nadine, Bahlo, Jasmin, Bergmann, Manuela, Byrd, John, Doehner, Hartmut, Eichhorst, Barbara, Else, Monica, Geisler, Christian, Grever, Michael, Lepretre, Stephane, Neuberg, Donna, Oscier, David, Rosenquist, Richard, Robak, Tadeusz, Shanafelt, Tait, Stilgenbauer, Stephan and Hallek, Michael (2015). The international prognostic index for patients with CLL(CLL-IPI) - an international meta-analysis. Leuk. Lymphoma, 56. S. 127 - 128. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Bahlo, Jasmin, Robrecht, Sandra, Franklin, Jeremy, Zhang, Can, Maurer, Christian, De Silva, Nisha, Lange, Elisabeth, Weide, Rudolf, Kiehl, Michael G., Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg, Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl-Anton, Boettcher, Sebastian, Stilgenbauer, Stephan, Fink, Anna Maria, Hallek, Michael and Eichhorst, Barbara (2020). Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). Hemasphere, 4 (1). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Kutsch, Nadine, Bahlo, Jasmin, Robrecht, Sandra, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael, Soekler, Martin, Schlag, Rudolf, Fink, Anna-Maria, Vehling-Kaiser, Ursula, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens, Klapper, Wolfram, Kreuzer, Karl-Anton, Boettcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael and Eichhorst, Barbara (2017). Health related quality of life (HRQOL) of patients treated with FCR vs BR within the CLL10 trial. Leuk. Lymphoma, 58. S. 109 - 111. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Busch, Raymonde, Bahlo, Jasmin, Mayer, Jiri, Hensel, Manfred, Hopfinger, Georg ORCID: 0000-0002-8321-1342, Hess, Georg, von Gruenhagen, Ulrich, Wendtner, Clemens-Martin, Fink, Anna Maria, Fischer, Kirsten, Hallek, Michael and Eichhorst, Barbara (2017). FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leuk. Lymphoma, 58 (2). S. 399 - 408. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Fink, Anna Maria, Federhen, Anno, Giza, Adam, Robrecht, Sandra, Stumpf, Janina, Stoltefuss, Andrea, Vehling-Kaiser, Ursula, Koenigsmann, Michael, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Illmer, Thomas, Schlag, Rudolf, Doerfel, Steffen, Gaska, Tobias, Kiehl, Michael G., Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2022). Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry. Blood, 140. S. 9879 - 9882. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kutsch, Nadine, Hallek, Michael and Eichhorst, Barbara (2015). Emerging therapies for refractory chronic lymphocytic leukemia. Leuk. Lymphoma, 56 (2). S. 285 - 293. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Holmes, Emily Eva, Robrecht, Sandra, Schueler, Gudrun, Vehling-Kaiser, Ursula, Decker, Thomas, Mueller-Hagen, Sigrun, Heinisch, Karin, Boettcher, Sebastian, Ritgen, Matthias, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Fink, Anna Maria, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Wendtner, Clemens-Martin (2023). Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Leuk. Lymphoma, 64 (2). S. 478 - 483. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Pallasch, Christian, Decker, Thomas ORCID: 0000-0003-3814-8775, Hebart, Holger, Chow, Kai Uwe, Graeven, Ullrich, Kisro, Jens, Kroeber, Alexander, Tausch, Eugen, Fischer, Kirsten, Fink, Anna-Maria, Wendtner, Clemens-Martin, Ritgen, Matthias, Stilgenbauer, Stephan, Zhang, Danjie, Li, Biao, Jurgensmeier, Juliane M., Rajakumaraswamy, Nishanthan, Bhargava, Pankaj, Hallek, Michael ORCID: 0000-0002-7425-4455 and Eichhorst, Barbara (2022). Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere, 6 (6). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna Maria, Pflug, Natali, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2015). Preliminary safety results of a placebo-controlled Phase III study of ibrutinib in treatment-nayve early stage CLL patients with risk of disease progression. Leuk. Lymphoma, 56. S. 20 - 22. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna-Maria, Pflug, Natali, von Tresckow, Julia, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Eckart, Michael J., Vehling-Kaiser, Ursula, Schlag, Rudolf, Balser, Christina, Mueller, Lothar, Reiser, Marcel, Wendtner, Clemens, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2017). Serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR) in early stage patients with CLL treated with ibrutinib or placebo: safety results of the ongoing randomized CLL12 phase III-trial. Leuk. Lymphoma, 58. S. 161 - 163. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna-Maria, Pflug, Natali, von Tresckow, Julia, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Eckart, Michael J., Vehling-Kaiser, Ursula, Schlag, Rudolf, Balser, Christina, Mueller, Lothar, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2015). Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Pflug, Natali, Fischer, Kirsten, Stilgenbauer, Stephan, Kreuzer, Karl Anton, Wendtner, Clemens-Martin, Eichhorst, Barbara and Hallek, Michael (2015). The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol., 11 (13). S. 1895 - 1904. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Gerwin, Henrik, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael J., Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens Martin, Reiser, Marcel, Stauch, Martina, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2020). Ibrutinib versus placebo in patients with asymptomatic, treatment-naive early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. Leuk. Lymphoma, 61. S. 18 - 21. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerbeins, Petra, Busch, Raymonde, Anheier, Nadine, Duerig, Jan, Bergmann, Manuela, Goebeler, Maria-Elisabeth, Hurtz, Hans-Juergen, Stauch, Martina B., Stilgenbauer, Stephan, Doehner, Hartmut, Fink, Anna-Maria, Cramer, Paula, Fischer, Kirsten, Wendtner, Clemens-Martin, Hallek, Michael and Eichhorst, Barbara (2014). Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am. J. Hematol., 89 (12). S. E239 - 5. HOBOKEN: WILEY. ISSN 1096-8652

Langerbeins, Petra and Eichhorst, Barbara (2021). Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic. Acta Haematol., 144 (5). S. 508 - 519. BASEL: KARGER. ISSN 1421-9662

Langerbeins, Petra, Eichhorst, Barbara and Hallek, Michael (2022). 72 years old male with an Incidental Finding of Lymphocytosis. Onkologie, 28. S. S137 - 7. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Langerbeins, Petra, Eichhorst, Barbara and Hallek, Michael (2019). Current treatment strategies for chronic lymphocytic leukemia. Onkologe, 25 (11). S. 1004 - 1009. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Langerbeins, Petra, Fuerstenau, Moritz, Gruell, Henning, Klein, Florian, Persigehl, Thorsten, Rybniker, Jan, Seeger-Nukpezah, Tamina, Kochanek, Matthias, Hallek, Michael, Eichhorst, Barbara, Koehler, Philipp ORCID: 0000-0002-7386-7495 and Boell, Boris (2020). COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia. Eur. J. Haematol., 105 (4). S. 508 - 512. HOBOKEN: WILEY. ISSN 1600-0609

Langerbeins, Petra, Zhang, Can, Robrecht, Sandra, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael Josef, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens-Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. Blood, 139 (2). S. 177 - 188. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Mato, Anthony R., Yazdy, Maryam Sarraf, Hill, Brian T., Shadman, Mazyar, Tuncer, Hande, Winter, Allison M., Kennard, Kaitlin, Allan, John N., Ujjani, Chaitra S., Brander, Danielle M., Nabhan, Chadi, Barr, Paul ORCID: 0000-0002-9733-401X, Brown, Jennifer R., Fox, Christopher P., Rhodes, Joanna, Schuh, Anna, Eyre, Toby A., Lamanna, Nicole, Jain, Nitin, Wierda, William G., Skarbnik, Alan P., Roeker, Lindsey E., Bannerji, Rajat, Evens, Andrew M., Lansigan, Frederick, Samp, Jennifer C., Nielsen, Jacqueline, Pauff, James M., Kipps, Thomas J., Schuster, Stephen J., Follows, George A., Cheson, Bruce and Eichhorst, Barbara (2018). Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Maurer, Christian, Pflug, Natali, Bahlo, Jasmin, Kluth, Sandra, Rhein, Christina, Cramer, Paula, Gross-Ophoff, Carolin, Langerbeins, Petra, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Fischer, Norbert, Tausch, Eugen, Stilgenbauer, Stephan, Boettcher, Sebastian, Doehner, Hartmut, Kneba, Michael, Dreyling, Martin, Binder, Mascha ORCID: 0000-0003-0663-3004, Hallek, Michael, Wendtner, Clemens-Martin, Bergmann, Manuela and Fischer, Kirsten (2016). Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. Eur. J. Haematol., 97 (3). S. 253 - 261. HOBOKEN: WILEY. ISSN 1600-0609

Mellinghoff, Sibylle C., Mayer, Leonie, Robrecht, Sandra, Weskamm, Leonie M., Dahlke, Christine ORCID: 0000-0002-2056-9195, Gruell, Henning, Schlotz, Maike, Vanshylla, Kanika ORCID: 0000-0003-4552-9170, Schloesser, Hans A., Thelen, Martin ORCID: 0000-0002-2785-9726, Fink, AnnaMaria, Fischer, Kirsten, Klein, Florian ORCID: 0000-0003-1376-1792, Addo, Marylyn M., Eichhorst, Barbara, Hallek, Michael and Langerbeins, Petra (2022). SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia. Haematologica, 107 (10). S. 2480 - 2485. PAVIA: FERRATA STORTI FOUNDATION. ISSN 1592-8721

Mellinghoff, Sibylle C., Robrecht, Sandra, Mayer, Leonie ORCID: 0000-0001-7102-4358, Weskamm, Leonie M., Dahlke, Christine, Gruell, Henning, Vanshylla, Kanika ORCID: 0000-0003-4552-9170, Schloesser, Hans A., Thelen, Martin ORCID: 0000-0002-2785-9726, Fink, Anna-Maria, Fischer, Kirsten, Klein, Florian, Addo, Marylyn M., Eichhorst, Barbara, Hallek, Michael and Langerbeins, Petra (2022). SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia, 36 (2). S. 562 - 566. LONDON: SPRINGERNATURE. ISSN 1476-5551

Mueller, Dirk, Fischer, Kirsten, Kaiser, Peter, Eichhorst, Barbara, Walshe, Ronald, Reiser, Marcel, Kellermann, Lenka, Borsi, Lisa, Civello, Daniele, Mensch, Alexander, Bahlo, Jasmin, Hallek, Michael, Stock, Stephanie and Fingerle-Rowson, Guenter (2016). Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk. Lymphoma, 57 (5). S. 1130 - 1140. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Munster, Pamela, Mita, Monica, Mahipal, Amit, Nemunaitis, John, Massard, Christophe, Mikkelsen, Tom, Cruz, Cristina, Paz-Ares, Luis, Hidalgo, Manuel, Rathkopf, Dana, Blumenschein, George, Jr., Smith, David C., Eichhorst, Barbara, Cloughesy, Tim, Filvaroff, Ellen H., Li, Shaoyi, Raymon, Heather, de Haan, Hans, Hege, Kristen and Bendell, Johanna C. (2019). First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag. Res., 11. S. 10463 - 10477. ALBANY: DOVE MEDICAL PRESS LTD. ISSN 1179-1322

Munster, Pamela N., Mahipal, Amit, Nemunaitis, John J., Mita, Monica M., Paz-Ares, Luis G., Massard, Christophe, Mikkelsen, Tom, Cruz, Cristina, Rathkopf, Dana E., Blumenschein, George R., Hidalgo, Manuel, Smith, David C., Eichhorst, Barbara, Cloughesy, Timothy Francis, Garrick, Brett, Trowe, Torsten, Filvaroff, Ellen, Hege, Kristen and Bendell, Johanna C. (2016). Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Pflug, Natali, Chakupurakal, Geothy, Fink, Anna-Maria, Robrecht, Sandra, Herling, Marco, Cramer, Paula, Holtick, Udo, Theurich, Sebastian ORCID: 0000-0001-5706-8258, Schetelig, Johannes, Fischer, Kirsten, Ritgen, Matthias, Scheid, Christof, Eichhorst, Barbara, Dreger, Peter, Hallek, Michael and von Bergwelt-Baildon, Michael (2021). Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies. Hemasphere, 5 (12). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Pflug, Natali, Cramer, Paula, Robrecht, Sandra, Bahlo, Jasmin, Westermann, Anne, Fink, Anna-Maria, Schrader, Alexandra, Mayer, Petra, Oberbeck, Sebastian, Seiler, Till, Zenz, Thorsten, Duerig, Jan, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael, Herling, Marco and Hopfinger, Georg (2019). New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk. Lymphoma, 60 (3). S. 649 - 658. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Pflug, Natali, Hopfinger, Georg, Cramer, Paula, Schrader, Alexandra, Weit, Nicole, Meister, Rita, Thiel, Miriam, Annolleck, Tanja, Westermann, Anne, Seiler, Till M., Zenz, Thorsten, Duerig, Jan, Bahlo, Jasmin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Fink, Anna-Maria, Eichhorst, Barbara, Hallek, Michael and Herling, Marco (2014). Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Pflug, Natali, Kluth, Sandra, Vehreschild, Joerg J., Bahlo, Jasmin, Tacke, Daniela, Biehl, Lena, Eichhorst, Barbara, Fischer, Kirsten, Cramer, Paula, Fink, Anna-Maria, von Bergwelt-Baildon, Michael, Stilgenbauer, Stephan, Hallek, Michael, Cornely, Oliver A. and Vehreschild, Maria J. G. T. (2016). Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. OncoImmunology, 5 (6). PHILADELPHIA: TAYLOR & FRANCIS INC. ISSN 2162-402X

Rhodes, Joanna, Sail, Kavita, Yazdy, Maryam, Hill, Brian, Shadman, Mazyar, Tuncer, Hande H., Winter, Allison, Kennard, Kaitlin, Allan, John, Ujjani, Chaitra, Brander, Danielle, Cho, Sang Kyu, Sharmokh, Simon, Jiang, Dingfeng, Nabhan, Chadi, Barr, Paul ORCID: 0000-0002-9733-401X, Brown, Jennifer, Fox, Christopher, Schuh, Anna, Eyre, Toby, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Wierda, William, Skarbnik, Alan, Roeker, Lindsey, Bannerji, Rajat, Evens, Andrew M., Pauff, James M., Schuster, Steven, Follows, George, Cheson, Bruce D., Eichhorst, Barbara and Mato, Anthony (2020). Factors impacting treatment selection in treatment-naive patients with CLL: a multicenter study. Leuk. Lymphoma, 61. S. 104 - 106. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Roberts, Andrew W., Ma, Shuo, Kipps, Thomas J., Coutre, Steven E., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Byrd, John C., Humphrey, Kathryn, Zhou, Lang, Chyla, Brenda, Nielsen, Jacqueline, Potluri, Jalaja, Kim, Su Young, Verdugo, Maria, Stilgenbauer, Stephan, Wierda, William G. and Seymour, John F. (2019). Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood, 134 (2). S. 111 - 123. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Roberts, Andrew W., Seymour, John F., Eichhorst, Barbara, Stilgenbauer, Stephan, Choi, Michael Y., Davids, Matthew S., Gerecitano, John F., Popovic, Relja, Chyla, Brenda, Zhu, Ming, Verdugo, Maria, Potluri, Jalaja, Lash, Leanne, Kim, Su Young and Hallek, Michael (2016). Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Ruchlemer, Rosa, Ben-Ami, Ronen ORCID: 0000-0003-0628-0798, Bar-Meir, Maskit, Brown, Jennifer R., Malphettes, Marion, Mous, Rogier, Tonino, Sanne H., Soussain, Carole, Barzic, Noelie, Messina, Julia A., Jain, Preetesh ORCID: 0000-0003-2735-168X, Cohen, Regev, Hill, Brian, Mulligan, Stephen P., Nijland, Marcel, Herishanu, Yair, Benjamini, Ohad, Tadmor, Tamar, Okamoto, Koh, Arthurs, Benjamin, Gottesman, Batsheva, Kater, Arnon P., Talha, Munir, Eichhorst, Barbara, Korem, Maya, Bogot, Naama, De Boer, Fransien, Rowe, Jacob M. and Lachish, Tamar (2019). Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. Mycoses, 62 (12). S. 1140 - 1148. HOBOKEN: WILEY. ISSN 1439-0507

Sachanas, Sotirios, Pangalis, Gerassimos A., Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Levidou, Georgia, Kyrtsonis, Marie-Christine, Bartzi, Vassiliki, Vassilakopoulos, Theodoros P., Kalpadakis, Christina, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Angelopoulou, Maria K., Eichhorst, Barbara and Hallek, Michael (2019). Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in Real-Life Outside of Clinical Trials. Anticancer Res., 39 (5). S. 2591 - 2599. ATHENS: INT INST ANTICANCER RESEARCH. ISSN 1791-7530

Schilhabel, Anke, Walter, Peter Jonas, Cramer, Paula ORCID: 0000-0003-4046-9922, von Tresckow, Julia, Kohlscheen, Saskia, Szczepanowski, Monika ORCID: 0000-0001-5482-8880, Laqua, Anna, Fischer, Kirsten, Eichhorst, Barbara, Boettcher, Sebastian, Schneider, Christof, Tausch, Eugen, Brueggemann, Monika, Kneba, Michael, Hallek, Michael ORCID: 0000-0002-7425-4455 and Ritgen, Matthias (2022). CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. Cancers, 14 (19). BASEL: MDPI. ISSN 2072-6694

Segura, Sonia Jaramillo, Agathangelidis, Andreas, Schneider, Christof, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Bloehdorn, Johannes, Hoechstetter, Manuela, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, Hallek, Michael, Doehner, Hartmut, Brandell, Richard Rosenquist, Ghia, Paolo, Stamatopoulos, Kostas and Stilgenbauer, Stephan (2020). Prognostic impact of common chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Leuk. Lymphoma, 61. S. 135 - 137. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Kim, Su Young, Wu, Jenny, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn and Kater, Arnon (2020). Time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): first presentation of 4-year data from the MURANO study. Leuk. Lymphoma, 61. S. 268 - 271. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole, Verdugo, Maria E., Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad and Kater, Arnon P. (2018). MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Shanafelt, Tait D., Parikh, Sameer A., Noseworthy, Peter A., Goede, Valentin, Chaffee, Kari G., Bahlo, Jasmin, Call, Timothy G., Schwager, Susan M., Ding, Wei, Eichhorst, Barbara, Fischer, Kirsten, Leis, Jose F., Chanan-Khan, Asher Alban, Hallek, Michael, Slager, Susan L. and Kay, Neil E. (2017). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk. Lymphoma, 58 (7). S. 1630 - 1640. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Simon, Florian, Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Cramer, Paula ORCID: 0000-0003-4046-9922, von Tresckow, Julia, Fuerstenau, Moritz, Goede, Valentin, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael ORCID: 0000-0002-7425-4455 and Al-Sawaf, Othman (2022). Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older. Leuk. Lymphoma, 63 (14). S. 3299 - 3307. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Coutre, Steven, Seymour, John F., Munir, Talha, Puvvada, Soham D., Wendtner, Clemens-Martin, Roberts, Andrew W., Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Boettcher, Sebastian, Mobasher, Mehrdad, Zhu, Ming, Desai, Monali, Chyla, Brenda, Verdugo, Maria, Enschede, Sari Heitner, Cerri, Elisa, Humerickhouse, Rod, Gordon, Gary, Hallek, Michael and Wierda, William G. (2016). Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol., 17 (6). S. 768 - 779. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Hillmen, Peter, Seymour, John F., Coutre, Steven, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Schuh, Anna, Assouline, Sarit, Wendtner, Clemens-Martin, Roberts, Andrew W., Davids, Matthew S., Bloehdorn, Johannes, Munir, Talha, Boettcher, Sebastian, Zhou, Lang, Salem, Ahmed Hamed, Desai, Monali, Chyla, Brenda, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Gordon, Gary, Hallek, Michael and Wierda, William G. (2018). Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol., 36 (19). S. 1973 - 1984. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Stilgenbauer, Stephan, Morschhauser, Franck, Wendtner, Clemens-Martin, Cartron, Guillaume, Hallek, Michael, Eichhorst, Barbara, Kozloff, Mark F., Giever, Thomas, Lozanski, Gerard, Jiang, Yanwen, Huang, Huang, Pignataro, Daniela Soriano, Schary, William, Humphrey, Kathryn, Mobasher, Mehrdad and Salles, Gilles (2018). Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Stilgenbauer, Stephan, Morschhauser, Franck, Wendtner, Clemens-Martin, Cartron, Guillaume, Hallek, Michael, Eichhorst, Barbara, Kozloff, Mark F., Giever, Thomas, Lozanski, Gerard, Jiang, Yanwen, Huang, Huang, Pignataro, Daniela Soriano, Schary, William, Humphrey, Kathryn, Mobasher, Mehrdad and Salles, Gilles (2021). Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). Haematologica, 106 (11). S. 2834 - 2845. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Tausch, Eugen, Schneider, Christof, Furstenau, Moritz, Robrecht, Sandra, Yosifov, Deyan Yordanov, Mertens, Daniel, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjoern, Janssens, Ann, Christiansen, Ilse, Noesslinger, Thomas, Baumann, Michael, Wendtner, Clemens-Martin, Eldering, Eric, Kreuzer, Karl-Anton, Ritgen, Matthias, Fink, Anna-Maria, Fischer, Kirsten, Kater, Arnon P., Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tausch, Eugen, Schneider, Christof, Robrecht, Sandra, Zhang, Can, Dolnik, Anna, Bloehdorn, Johannes, Bahlo, Jasmin, Al-Sawaf, Othman, Ritgen, Matthias, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Tandon, Maneesh, Humphrey, Kathryn, Jiang, Yanwen, Schary, William, Bullinger, Lars, Mertens, Daniel, Lura, Michele Porro, Kneba, Michael, Doehner, Hartmut, Fischer, Kirsten, Hallek, Michael and Stilgenbauer, Stephan (2020). Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood, 135 (26). S. 2402 - 2413. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Thijssen, Rachel ORCID: 0000-0002-4493-306X, ter Burg, Johanna, Garrick, Brett, van Bochove, Gregor G. W., Brown, Jennifer R., Fernandes, Stacey M., Sole Rodriguez, Maria, Michot, Jean-Marie ORCID: 0000-0003-3482-3331, Hallek, Michael, Eichhorst, Barbara, Reinhardt, Hans Christian, Bendell, Johanna, Derks, Ingrid A. M., van Kampen, Roel J. W., Hege, Kristen, Kersten, Marie Jose, Trowe, Torsten, Filvaroff, Ellen H., Eldering, Eric and Kater, Arnon P. (2016). Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood, 128 (4). S. 574 - 584. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio ORCID: 0000-0002-5157-4376, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias ORCID: 0000-0002-9615-9432, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas and Ghia, Paolo (2022). Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study. Blood, 140. S. 2333 - 2338. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Wendtner, Clemens-Martin, Byrd, John C., Eichhorst, Barbara, Foa, Robin, Hallek, Michael, Hillmen, Peter, Jager, Ulrich, Jurczak, Wojciech, Kelemen, Peter, Laribi, Kamel, Munir, Talha, Staber, Philipp B., Stilgenbauer, Stephan and Woyach, Jennifer Ann (2016). A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE). J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Wierda, William, Chyla, Brenda, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Wendtner, Clemens-Martin, Davids, Matthew, Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Stilgenbauer, Stephan and Hallek, Michael (2017). Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial. Clin. Lymphoma Myeloma Leuk., 17. S. S303 - 1. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Wolf, Christine, Garding, Angela, Filarsky, Katharina, Bahlo, Jasmin, Robrecht, Sandra, Becker, Natalia, Zucknick, Manuela ORCID: 0000-0003-1317-7422, Rouhi, Arefeh, Weigel, Anja, Claus, Rainer ORCID: 0000-0003-2617-8766, Weichenhan, Dieter, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael, Kuchenbauer, Florian, Plass, Christoph, Doehner, Hartmut, Stilgenbauer, Stephan, Lichter, Peter and Mertens, Daniel ORCID: 0000-0003-0227-7188 (2018). NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int. J. Cancer, 142 (2). S. 322 - 334. HOBOKEN: WILEY. ISSN 1097-0215

Yosifov, Deyan Yordanov ORCID: 0000-0002-5473-4398, Idler, Irina, Bhattacharya, Nupur, Reichenzeller, Michaela, Close, Viola, Ezerina, Daria ORCID: 0000-0002-3104-7093, Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Kugler, Sabrina, Bloehdorn, Johannes, Bahlo, Jasmin, Robrecht, Sandra, Eichhorst, Barbara, Fischer, Kirsten, Weigel, Anja, Busch, Hauke ORCID: 0000-0003-4763-4521, Lichter, Peter, Doehner, Hartmut, Dick, Tobias P., Stilgenbauer, Stephan and Mertens, Daniel ORCID: 0000-0003-0227-7188 (2020). Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia, 34 (1). S. 115 - 128. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Zenz, Thorsten, Eichhorst, Barbara, Busch, Raymonde, Denzel, Tina, Haebe, Sonja, Winkler, Dirk, Buehler, Andreas, Edelmann, Jennifer, Bergmann, Manuela, Hopfinger, Georg ORCID: 0000-0002-8321-1342, Hensel, Manfred, Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan (2010). TP53 Mutation and Survival in Chronic Lymphocytic Leukemia. J. Clin. Oncol., 28 (29). S. 4473 - 4480. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Klaproth, Holger, Tausch, Eugen, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2015). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Bottcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Eichhorst, Barbara, Bahlo, Jasmin and Hallek, Michael (2019). The Treatment of Chronic Lymphatic Leukemia. Dtsch. Arztebl. Int., 116 (4). S. 41 - 47. COLOGNE: DEUTSCHER AERZTE-VERLAG GMBH. ISSN 1866-0452

von Tresckow, Julia, Hallek, Michael and Eichhorst, Barbara (2018). Individualized Therapy of chronic lymphocytic Leukemia. Dtsch. Med. Wochenschr., 143 (18). S. 1318 - 1325. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413

This list was generated on Fri Mar 29 11:16:20 2024 CET.